Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Treasury Shares (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Treasury Shares for 6 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 12.39% to $5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 12.39% increase, with the full-year FY2025 number at $5.2 million, up 12.39% from a year prior.
  • Treasury Shares was $2.4 million for Q4 2025 at Lexicon Pharmaceuticals, roughly flat from $2.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.4 million in Q1 2025 to a low of $867973.0 in Q2 2023.
  • A 3-year average of $1.6 million and a median of $1.5 million in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: soared 59.97% in 2024, then grew 12.39% in 2025.
  • Lexicon Pharmaceuticals' Treasury Shares stood at $2.9 million in 2023, then skyrocketed by 59.97% to $4.6 million in 2024, then grew by 12.39% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Treasury Shares are $5.2 million (Q4 2025), $5.2 million (Q3 2025), and $5.2 million (Q2 2025).